SCHEMBL6802820

SCHEMBL6802820

CC(=O)c1cc(Cl)sc1Oc1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.43
RAB9A P51151 4/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 2/20 0.40
P2RY14 Q15391 1/20 0.40
HPGD P15428 4/20 0.40
CXCL8 P10145 2/20 0.39
PARP10 Q53GL7 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
MAPT P10636 4/20 0.39
NPC1 O15118 3/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
MAPK8 P45983 1/20 0.37
MRGPRX1 Q96LB2 1/20 0.36
GCK P35557 1/20 0.36
PTGER4 P35408 1/20 0.36
MEN1 O00255 1/20 0.36
ALOX15 P16050 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6802805 0.87 RAB9A (0.43) KMT2ARAB9AMAPK1HTTHPGD
SCHEMBL8079069 0.86 HPGD (0.38) KMT2AMAPK1HTTP2RY14HPGD
SCHEMBL6803041 0.81 RAB9A (0.48) RAB9AMAPK1HTTP2RY14HPGD
SCHEMBL6800391 0.81 HPGD (0.43) RAB9AHTTHPGDSMN1; SMN2MAPT
SCHEMBL6803640 0.78 MAPK1 (0.42) KMT2ARAB9AMAPK1HTTHPGD
SCHEMBL6801935 0.77 MAPK1 (0.42) KMT2AMAPK1HTTP2RY14HPGD
SCHEMBL27679501 0.75 KMT2A (0.61) KMT2AHTTCXCL8PARP10SMN1; SMN2
SCHEMBL9762806 0.66 PARP10 (0.71) RAB9AHPGDPARP10MAPT
SCHEMBL11305101 0.66 MEN1 (0.55) KMT2ARAB9APARP10SMN1; SMN2MAPT
SCHEMBL756054 0.66 MAOB (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds PFIZER INC. 2004-07-22 US disclosed
US-6696470-B2 FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. PFIZER INC. 2004-02-24 US disclosed
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds KAWAI AKIYOSHI (JP) 2002-02-21 US disclosed
EP-0853083-B1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER (US) 2001-09-12 EP disclosed
US-6048880-A THERAPY FOR CYTOKINE SENSITIVE DISEASES PFIZER PHARAMACEUTICALS INC. (JP) 2000-04-11 US disclosed
EP-0853083-A1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER INC. (US) 1998-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds MC2R, FCGR2A, OGFR KMT2A 4178/4885RAB9A 3625/4885MAPK1 1354/4885
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds MC2R, CRHR1, NR3C2 KMT2A 4224/4885RAB9A 4094/4885MAPK1 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.